Corrigendum to "A naturalistic retrospective evaluation of the utility of pharmacogenetic testing based on CYP2D6 and CYP2C19 profiling in antidepressants treatment in a cohort of patients with major depressive disorder" [Progress in Neuropsychopharmacology and Biological Psychiatry (2025) 111292].

IF 5.3 2区医学 Q1 CLINICAL NEUROLOGY

Progress in Neuro-Psychopharmacology & Biological Psychiatry Pub Date : 2025-07-21 DOI:10.1016/j.pnpbp.2025.111453

Alessio Squassina, Pasquale Paribello, Marco Pinna, Martina Contu, Claudia Pisanu, Donatella Congiu, Giovanni Severino, Anna Meloni, Andrea Carta, Claudio Conversano, Francesco Mola, Maria Del Zompo, Federico Bernoni d'Aversa, Alessandra Minelli, Massimo Gennarelli, Federica Pinna, Bernardo Carpiniello, Mirko Manchia

引用次数: 0

查看原文本刊更多论文

“基于CYP2D6和CYP2C19分析的药物遗传学检测在重度抑郁症患者抗抑郁药物治疗中的应用的自然回顾性评估”的勘误表[神经精神药理学和生物精神病学进展（2025）111292]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Progress in Neuro-Psychopharmacology & Biological Psychiatry 医学-精神病学

CiteScore

12.00

自引率

1.80%

发文量

153

审稿时长

56 days

期刊介绍： Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Issues of the journal are regularly devoted wholly in or in part to a topical subject. Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated.